JW Lifescience (A234080) Stock Overview
Provides national infusion solutions in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
A234080 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
JW Lifescience Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,930.00 |
| 52 Week High | ₩15,580.00 |
| 52 Week Low | ₩11,330.00 |
| Beta | 0.33 |
| 1 Month Change | 2.46% |
| 3 Month Change | 0.15% |
| 1 Year Change | 11.95% |
| 3 Year Change | 7.48% |
| 5 Year Change | -31.22% |
| Change since IPO | -39.79% |
Recent News & Updates
Recent updates
Solid Earnings Reflect JW Lifescience's (KRX:234080) Strength As A Business
Nov 24
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year
Mar 11What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?
Feb 21Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?
Feb 02
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?
Dec 23Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 23How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?
Nov 27Shareholder Returns
| A234080 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -0.2% | -2.5% | 1.6% |
| 1Y | 11.9% | 35.0% | 147.0% |
Return vs Industry: A234080 underperformed the KR Pharmaceuticals industry which returned 35% over the past year.
Return vs Market: A234080 underperformed the KR Market which returned 147% over the past year.
Price Volatility
| A234080 volatility | |
|---|---|
| A234080 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A234080 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A234080's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 296 | Sungnam Cha | www.jw-lifescience.co.kr |
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd.
JW Lifescience Corporation Fundamentals Summary
| A234080 fundamental statistics | |
|---|---|
| Market cap | ₩200.22b |
| Earnings (TTM) | ₩28.61b |
| Revenue (TTM) | ₩257.83b |
Is A234080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A234080 income statement (TTM) | |
|---|---|
| Revenue | ₩257.83b |
| Cost of Revenue | ₩185.58b |
| Gross Profit | ₩72.25b |
| Other Expenses | ₩43.65b |
| Earnings | ₩28.61b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.85k |
| Gross Margin | 28.02% |
| Net Profit Margin | 11.09% |
| Debt/Equity Ratio | 22.2% |
How did A234080 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/02 08:41 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JW Lifescience Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tae Young Lee | KB Securities Co., Ltd. |
| Changmin Yoon | Shinhan Investment Corp. |